Evaxion Biotech Appeals Nasdaq Delisting Decision
Company Announcements

Evaxion Biotech Appeals Nasdaq Delisting Decision

Evaxion Biotech (EVAX) has released an update.

Evaxion Biotech has received a delisting determination from Nasdaq due to insufficient stockholder equity but has appealed the decision and requested a hearing to seek an additional 180-day extension. The company remains committed to maintaining its Nasdaq listing by increasing equity through business development and capital market activities. Despite challenges in the current market environment, Evaxion is in ongoing discussions with Nasdaq to regain compliance.

For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyEvaxion Biotech receives, appeals delisting determination from Nasdaq
TipRanks Auto-Generated NewsdeskEvaxion Biotech Plans Strategic Capital Increase
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App